Five-Transcript Host Signature for Viral–Bacterial Pneumonia Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for pneumonia lack specificity in differentiating between viral and bacterial causes, leading to misdiagnosis, unnecessary medical interventions, and ineffective antibiotic prescriptions.
Innovation Solution
Identification of a 5-transcript host signature comprising genes MXRA7, FAM20A, BAG3, TDRD9, and KLF14 for differential diagnosis, using gene expression analysis in blood samples to distinguish between viral and bacterial pneumonia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods (nonspecific symptoms, chest imaging, laboratory analysis) are used, then diagnostic coverage is maintained, but diagnostic precision and ability to differentiate viral vs bacterial pneumonia deteriorates
Solution Approach 1:
The patent segments the diagnostic process by identifying specific gene expression profiles (biomarkers) that distinguish viral from bacterial pneumonia. Instead of using a single complex diagnostic method, the invention divides the diagnostic challenge into detectable molecular signatures that can be measured independently, thereby improving precision without proportionally increasing overall system complexity.
Solution Approach 2:
The patent introduces gene expression biomarkers as intermediary molecules that mediate between the pneumonia condition and the diagnostic measurement. These biomarkers serve as intermediate indicators that translate the complex biological state into measurable signals, enabling more precise differentiation between viral and bacterial causes while using established molecular biology techniques.
2Reliability
If gene expression analysis is used to differentiate viral and bacterial pneumonia, then diagnostic accuracy improves, but test complexity and cost increase
Solution Approach 1:
The patent changes the diagnostic parameter from clinical observations and general laboratory markers to specific gene expression levels. By measuring the expression patterns of particular genes associated with viral or bacterial infections, the test achieves higher reliability. This parameter change leverages established RT-PCR and gene expression analysis technology, improving diagnostic confidence while using existing molecular biology infrastructure.
3Reliability
If misdiagnosis is reduced through better differentiation methods, then inappropriate antibiotic use decreases, but diagnostic time and resources increase
Solution Approach 1:
The patent performs preliminary molecular characterization of the infection by detecting specific gene expression profiles early in the diagnostic process. By identifying viral vs bacterial etiology through biomarker analysis before final diagnosis, the system enables earlier and more accurate treatment decisions. This preliminary molecular assessment prevents delayed diagnosis and inappropriate antibiotic prescribing while streamlining the overall diagnostic workflow.
Data Source
Figure 1
Figure 2A~2B
Figure 2C
AI summary
The present invention refers to an in vitro method for identifying biomarkers or biomarker signatures for the differential diagnosis between viral and bacterial pneumonia in a patient, for the differential diagnosis between viral and bacterial pneumonia in a patient and/or for selecting a therapy for a patient suffering from pneumonia.